Cell Manufacturing

Our human Stem-SPACE™ technology platform leverages discovery of functionally discrete single cells and precise control over the development process from lab-grown stem cells.

TRADITIONAL METHODS PREVENT MANUFACTURING OF POTENT CELLS

Focusing on cell type doesn’t capture rare cell types that affect desired potency.

Unhealthy autologous donor cells create high variability in quality of raw source material.

Lower rate of cell expansion / differentiation creates less manufacturing yield at high costs.

OUR VERSATILE PLATFORM

Enabling Exponential Expansion of Human Stem Cells

The technology platform harnesses the incredible potential of healthy umbilical cord derived blood stem cells as a starting material to expand and manufacture potent stem cells for clinical use.

Enabling Large Scale Differentiation of Rare Immune Cells

The technology platform achieves controlled and well-characterized differentiation process by mimicking developmental process of blood formation in a dish to produce a broad arsenal of rare immune cell types.

Platform Differentiation

Begins with donor-derived cord blood stem cells
Manufacturing process enriches potent cell sub-type
Our novel approach does not require gene editing
Off-the-shelf approach for rapid delivery within days
Scalable manufacturing of multiple doses from one healthy donor
High tolerability and persistence of cells

Mapping the tumor microenvironment by single-cell genomics to reveal specialized population of immune cells amenable to therapeutic intervention.

Vishwakarma et al, Nature Communications Biology (2021)

Disruptive CGT technology assets under management

"At Cell BioEngines, we leverage the natural biology of cells for large scale manufacturing. Each cord unit allows 10-100’s of doses (many patients) per manufacturing run providing unparalleled scalability" - Founder & CEO

Learn more